GlassScriptPhysician profile
Gina L Weir
NPI 1720309263
$10,194.09
in general payments reported to CMS, 2019-2025
33 companies · $1,404 in 2025
The $1,404 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,103 · 2020: $1,111 · 2021: $1,511 · 2022: $1,302 · 2023: $1,525 · 2024: $1,238 · 2025: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,067 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,066.85 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,925.53 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $958.85 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $909.90 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $723.07 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $684.45 | 2021-2025 | |
| Amgen INC. | $665.29 | 2019-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $526.98 | 2019-2025 | |
| Ucb, INC. | $298.53 | 2019-2025 | Bimzelx |
| Pfizer INC. | $260.73 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $231.80 | 2019-2025 | |
| Incyte Corporation | $216.11 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $212.47 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $197.68 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $174.39 | 2019-2020 | |
| Genentech USA, INC. | $161.42 | 2019-2023 | Erivedge |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $134.07 | 2019-2020 | |
| Celgene Corporation | $133.71 | 2019 | |
| Almirall LLC | $131.27 | 2021-2023 | Seysara |
| Galderma Laboratories, L.P. | $115.21 | 2019-2025 | Nemluvio, Aklief |
| Dusa Pharmaceuticals, INC. | $93.87 | 2019 | |
| Leo Pharma INC. | $79.89 | 2021-2025 | Adbry |
| Mayne Pharma Commercial LLC | $69.44 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $48.01 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.79 | 2023-2024 | Spevigo, Cyltezo |
| Organon LLC | $35.18 | 2023-2025 | Vtama |
| Botanix Sb INC | $32.74 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $31.30 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $23.19 | 2020 | |
| Kyowa Kirin, INC. | $18.32 | 2022 | |
| Chiesi USA, INC. | $16.37 | 2025 | Filsuvez |
| Promius Pharma LLC | $16.08 | 2019 | |
| Aclaris Therapeutics, INC. | $13.87 | 2019 | |
| Biofrontera INC. | $8.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.